PPT-USE OF ANTIPLATELET THERAPY IN PATIENTS WITH DIABETES

Working Group Maria E Wolfs MD FRCP Rémi RabasaLhoret MD PhD Canadian Cardiovascular Society Antiplatelet Guidelines Objectives Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet . People with diabetes have high blood glucose also called high blood sugar or hyperglycemia Diabetes is a disorder of metabolism the way the body uses digested food for energy The digestive tract breaks down carbohydratessugars and starches found in Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. Anne Daly, MS, RDN, BC-ADM, CDE. Southern Illinois . Univ. School of Medicine. Center for Family & Community Medicine. OBJECTIVES OF TALK. To review the goals of medical nutrition therapy (MNT), evidence for effectiveness & key MNT messages for PWD. Jonathan G. . Marquess, . PharmD. , CDE, . FAPhA. President/CEO, The Institute for Wellness and Education, Inc.. & . Multiple Independent Pharmacy Owner. Woodstock. , Georgia. Program Faculty. Dr. Jonathan Marquess is the President of The Institute for Wellness and Education, a Disease Management Company. He is owner and diabetes educator at two AADE recognized Diabetes Education Centers in Atlanta. In Addition, Dr. Marquess, and his Pharmacist wife, Pam, are the owners . Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . Thomas Savides, M.D.. Professor of Clinical Medicine. University of California, San Diego. Disclosures. None. Learning Objectives. Accurately assess the risk of bleeding in patients on anticoagulants and antiplatelet agents before endoscopic procedures. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Discover the truth and the facts about Halki Diabetes Remedy Ingredients™ PDF, eBook by Eric Whitfield. Click \"SHARE\" and \"DOWNLOAD\" to read the document offline. Anticoagulant therapy. (n = . 124). CADISS. P. rimary outcome. : . Ipsilateral . stroke or all-cause mortality . for antiplatelet vs. anticoagulation: 2. % . vs. 1%; p . = . 0.63. Any stroke: 2% vs. 1%, . People with diabetes have a 2 to 4 fold higher risk of dying from cardiovascular disease. People with diabetes have a complex procoagulant state, which contributes to the increased risk of atheroscler Type II and Pre Diabetes Eat Right 4 Your Type | Featuring brandnew targeted food and supplement lists specific to diabetes that readers wont find anywhere elseAmericas fastestgrowing health problem just got dealt a major blow Dr Peter J DAdamo the creator of the Blood Type Diet which has forever c 12. inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study. Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, MD. intracerebral haemorrhage (ICH): extended follow-up of the. RE. start. or . ST. op. . A. ntithrombotics. . R. andomised . T. rial. (RESTART) . RESTART Collaboration. www.RESTARTtrial.org. Intracerebral haemorrhage (ICH) is associated with an increased risk of arterial ischaemic events*: pooled analysis of 4 population-based cohorts.